132 related articles for article (PubMed ID: 2727475)
1. The bias of the sample proportion following a group sequential phase II clinical trial.
Chang MN; Wieand HS; Chang VT
Stat Med; 1989 May; 8(5):563-70. PubMed ID: 2727475
[TBL] [Abstract][Full Text] [Related]
2. A simple and efficient bias-reduced estimator of response probability following a group sequential phase II trial.
Guo HY; Liu A
J Biopharm Stat; 2005; 15(5):773-81. PubMed ID: 16078384
[TBL] [Abstract][Full Text] [Related]
3. On the estimation of the binomial probability in multistage clinical trials.
Jung SH; Kim KM
Stat Med; 2004 Mar; 23(6):881-96. PubMed ID: 15027078
[TBL] [Abstract][Full Text] [Related]
4. Estimation of the log-normal mean.
Zhou XH
Stat Med; 1998 Oct; 17(19):2251-64. PubMed ID: 9802182
[TBL] [Abstract][Full Text] [Related]
5. Supplementary analysis of probabilities at the termination of a group sequential phase II trial.
Liu A; Wu C; Yu KF; Gehan E
Stat Med; 2005 Apr; 24(7):1009-27. PubMed ID: 15565737
[TBL] [Abstract][Full Text] [Related]
6. Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data.
Shimura M; Gosho M; Hirakawa A
Stat Med; 2017 Jun; 36(13):2067-2080. PubMed ID: 28211076
[TBL] [Abstract][Full Text] [Related]
7. Point estimation following a two-stage group sequential trial.
Grayling MJ; Wason JM
Stat Methods Med Res; 2023 Feb; 32(2):287-304. PubMed ID: 36384365
[TBL] [Abstract][Full Text] [Related]
8. Conditional estimation using prior information in 2-stage group sequential designs assuming asymptotic normality when the trial terminated early.
Shimura M; Maruo K; Gosho M
Pharm Stat; 2018 Sep; 17(5):400-413. PubMed ID: 29687592
[TBL] [Abstract][Full Text] [Related]
9. A comparison of estimation methods adjusting for selection bias in adaptive enrichment designs with time-to-event endpoints.
Di Stefano F; Pannaux M; Correges A; Galtier S; Robert V; Saint-Hilary G
Stat Med; 2022 May; 41(10):1767-1779. PubMed ID: 35098579
[TBL] [Abstract][Full Text] [Related]
10. Reduction of bias in estimating the frequency of recessive genes.
Huether CA; Murphy EA
Am J Hum Genet; 1980 Mar; 32(2):212-22. PubMed ID: 7386457
[TBL] [Abstract][Full Text] [Related]
11. Estimation After a Group Sequential Trial.
Milanzi E; Molenberghs G; Alonso A; Kenward MG; Tsiatis AA; Davidian M; Verbeke G
Stat Biosci; 2015 Oct; 7(2):187-205. PubMed ID: 26478751
[TBL] [Abstract][Full Text] [Related]
12. Estimation of secondary endpoints in two-stage phase II oncology trials.
Kunz CU; Kieser M
Stat Med; 2012 Dec; 31(30):4352-68. PubMed ID: 22930470
[TBL] [Abstract][Full Text] [Related]
13. Empirical Bayes estimation of posterior probabilities of enrichment: a comparative study of five estimators of the local false discovery rate.
Yang Z; Li Z; Bickel DR
BMC Bioinformatics; 2013 Mar; 14():87. PubMed ID: 23497228
[TBL] [Abstract][Full Text] [Related]
14. A note on point estimation of the hazard ratio in exponential distributions.
Lui KJ; Rhodes P
Stat Med; 1990 Oct; 9(10):1167-73. PubMed ID: 2247717
[TBL] [Abstract][Full Text] [Related]
15. Rapid report on estimating incidence from cross-sectional data.
DeMonte JB; Neilan AM; Loop MS; Ciaranello AL; Hudgens MG
Ann Epidemiol; 2021 Jan; 53():106-108.e1. PubMed ID: 32979470
[TBL] [Abstract][Full Text] [Related]
16. Conditional bias of point estimates following a group sequential test.
Fan XF; DeMets DL; Lan KK
J Biopharm Stat; 2004 May; 14(2):505-30. PubMed ID: 15206542
[TBL] [Abstract][Full Text] [Related]
17. Optimised point estimators for multi-stage single-arm phase II oncology trials.
Grayling MJ; Mander AP
J Biopharm Stat; 2022 Nov; 32(6):817-831. PubMed ID: 35196204
[TBL] [Abstract][Full Text] [Related]
18. Interval estimation of risk ratio in the simple compliance randomized trial.
Lui KJ
Contemp Clin Trials; 2007 Feb; 28(2):120-9. PubMed ID: 16820329
[TBL] [Abstract][Full Text] [Related]
19. Estimation of the binomial probabilities in a two-stage phase II clinical trial with two co-primary endpoints.
Sun Y; Zhang X; Tan X; Tu D
Contemp Clin Trials; 2021 Jun; 105():106390. PubMed ID: 33819639
[TBL] [Abstract][Full Text] [Related]
20. P-value calculation for multistage phase II cancer clinical trials.
Jung SH; Owzar K; George SL; Lee T
J Biopharm Stat; 2006; 16(6):765-75; discussion 777-83. PubMed ID: 17146978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
